[Succinate dehydrogenase in cancer].
Rôle de la succinate déshydrogénase dans le cancer.
Journal
Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
7
4
2022
Statut:
ppublish
Résumé
Succinate dehydrogenase (SDH) is a mitochondrial enzyme that participates in both the tricarboxylic acid cycle and the electron transport chain. Mutations in genes encoding SDH are responsible for a predisposition to pheochromocytomas and paragangliomas, and more rarely, to gastrointestinal stromal tumors or renal cell carcinomas. A decrease in SDH activity, not explained by genetics, has also been observed in more common cancers. One of the consequences of the inactivation of SDH is the excessive production of its substrate, succinate, which acts as an oncometabolite by promoting a pseudohypoxic status and an extensive epigenetic rearrangement. Understanding SDH-related oncogenesis now makes it possible to develop innovative diagnostic methods and to consider targeted therapies for the management of affected patients. Rôle de la succinate déshydrogénase dans le cancer. La succinate déshydrogénase (SDH) est une enzyme mitochondriale qui participe au cycle de Krebs et à la chaîne respiratoire. Quand elles sont à l’origine de cancers, les mutations des gènes codant les différentes sous-unités de la SDH sont responsables d’une prédisposition aux phéochromocytomes et aux paragangliomes, et, plus rarement, aux tumeurs stromales gastro-intestinales ou au cancer du rein. Une diminution de l’activité de la SDH, non expliquée par la génétique, s’observe aussi dans certains cancers plus fréquents. Une des conséquences de l’inactivation de la SDH est la production excessive de son substrat, le succinate, qui joue un rôle d’oncométabolite en promouvant un statut pseudohypoxique et d’importants remaniements épigénétiques. La compréhension de l’oncogenèse liée à la succinate déshydrogénase permet aujourd’hui de développer des méthodes diagnostiques innovantes et d’envisager des thérapies ciblées pour la prise en charge des patients atteints.
Autres résumés
Type: Publisher
(fre)
Rôle de la succinate déshydrogénase dans le cancer.
Identifiants
pubmed: 35333162
doi: 10.1051/medsci/2022024
pii: msc200647
doi:
Substances chimiques
Succinate Dehydrogenase
EC 1.3.99.1
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
255-262Subventions
Organisme : Fondation pour la Recherche Médicale
ID : FDM201806005916
Informations de copyright
© 2022 médecine/sciences – Inserm.
Références
Bourgeron TRustin P, Chretien D, et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet 1995 ; 11 : 144–149.
Warburg O. On the origin of cancer cells. Science 1956 ; 123 : 309–314.
Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000 ; 287 : 848–851.
Lenders JWM,Kerstens MN, Amar L, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 2020; 38 : 1443–56.
Favier J, Amar L, Gimenez-Roqueplo APParaganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 2015 ; 11 : 101–111.
Ni Y, Seballos S, Ganapathi S, et al. Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer. Endocr Relat Cancer 2015 ; 22 : 121–130.
Niemeijer ND, Papathomas TG, Korpershoek E, et al. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab 2015 ; 100 : E1386–E1393.
Xekouki P, Pacak K, Almeida M, et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH?. J Clin Endocrinol Metab 2012 ; 97 : E357–E366.
Haller F, Moskalev EA, Faucz FR, et al. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 2014 ; 21 : 567–577.
Weinhold N, Jacobsen A, Schultz N, et al. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet 2014 ; 46 : 1160–1165.
Sciacovelli M, Guzzo G, Morello V, et al. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab 2013 ; 17 : 988–999.
Bénit P, Kahn A, Chretien D, et al. Evolutionarily conserved susceptibility of the mitochondrial respiratory chain to SDHI pesticides and its consequence on the impact of SDHIs on human cultured cells. PLoS One 2019 ; 14 : e0224132.
Morin A, Letouze E, Gimenez-Roqueplo AP, et al. Oncometabolites-driven tumorigenesis: From genetics to targeted therapy. Int J Cancer 2014 ; 135 : 2237–2248.
Gimenez-Roqueplo AP, Favier J, Rustin P, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 2001 ; 69 : 1186–1197.
Kim E, Rath EM, Tsang VHM, et al. Structural and functional consequences of succinate dehydrogenase subunit B mutations. Endocr Relat Cancer 2015 ; 22 : 387–397.
Burnichon N, Mazzella J-M, Drui D, et al. Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma. J Med Genet 2017 ; 54 : 125–133.
Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007 ; 92 : 3822–3828.
Hescot S, Curras-Freixes M, Deutschbein T, et al. Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab 2019 ; 104 : 2367–2374.
Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009 ; 94 : 2817–2827.
Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011 ; 108 : 314–318.
Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008 ; 100 : 1260–1262.
Losman J-A, Koivunen P, Kaelin WG. 2-Oxoglutarate-dependent dioxygenases in cancer. Nat Rev Cancer 2020; 20 : 710–26.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 ; 144 : 646–674.
Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001 ; 292 : 468–472.
Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001 ; 292 : 464–468.
Favier J, Brière JJ, Burnichon N, et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE 2009 ; 4(9): e7094.
Gimenez-Roqueplo AP, Favier J, Rustin P, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 2001 ; 69 : 1186–1197.
Briere JJ, Favier J, Benit P, et al. Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum Mol Genet 2005 ; 14 : 3263–3269.
Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005 ; 7 : 77–85.
Dahia PL, Ross KN, Wright ME, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005 ; 1 : 72–80.
Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010 ; 19 : 3011–3020.
Morin A, Goncalves J, Moog S, et al. TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition. Cell Rep 2020; 30 : 4551–66.e7.
Bechmann N, Moskopp ML, Ullrich M, et al. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocr Relat Cancer 2020; 27 : 625–40.
Seifert V, Richter S, Bechmann N, et al. HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models. Cancers (Basel) 2021; 13 : 385.
Loriot C, Burnichon N, Gadessaud N, et al. Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused by SDHB Gene Mutations. J Clin Endocrinol Metab 2012 ; 97 : E954–E962.
Loriot C, Domingues M, Berger A, et al. Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget 2015 ; 6 : 32955–32965.
Toledo RA. New HIF2alpha inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas. Endocr Relat Cancer 2017 ; 24 : C9–19.
Letouze E, Martinelli C, Loriot C, et al. SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell 2013 ; 23 : 739–752.
Killian JK, Kim SY, Miettinen M, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov 2013 ; 3 : 648–657.
Eisenhofer G, Pacak K, Huynh TT, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011 ; 18 : 97–111.
Sulkowski PL, Sundaram RK, Oeck S, et al. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet 2018 ; 50 : 1086–1092.
Cardaci S, Zheng L, MacKay G, et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol 2015 ; 17 : 1317–1326.
Lussey-Lepoutre C, Hollinshead KE, Ludwig C, et al. Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat Commun 2015 ; 6 : 8784.
Goncalves J, Moog S, Morin A, et al. Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate. Cancer Res 2021; 81 : 3480–94.
Liu Y, Pang Y, Zhu B, et al. Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. Clin Cancer Res 2020; 26 : 3868–80.
Ngo B, Van Riper JM, Cantley LC, et al. Targeting cancer vulnerabilities with high-dose vitamin C. Nat Rev Cancer 2019 ; 19 : 271–282.
Wu J-Y, Huang T-W, Hsieh Y-T, et al. Cancer-Derived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor. Mol Cell 2020; 77 : 213–27.e5.
Mu X, Zhao T, Xu C, et al. Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation. Oncotarget 2017 ; 8 : 13174–13185.
Broudin C, Favier J, Verkarre V, et al. [Pathologist contribution in the diagnosis of hereditary predisposition to paranganglioma and pheochromocytoma]. Ann Pathol 2020; 40 : 134–41.
Hoekstra AS, de Graaff MA, Briaire-de Bruijn IH, et al. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. Oncotarget 2015 ; 6 : 38777–38788.
Richter S, Peitzsch M, Rapizzi E, et al. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab 2014 ; 99 : 3903–3911.
Lussey-Lepoutre C, Bellucci A, Morin A, et al. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma. Clin Cancer Res 2016 ; 22 : 1120–1129.
Varoquaux A, le Fur Y, Imperiale A, et al. Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. Endocr Relat Cancer 2015 ; 22 : M1–M8.
Lussey-Lepoutre C, Bellucci A, Burnichon N, et al. Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. Eur J Nucl Med Mol Imaging 2020; 47 : 1510–7.
Hadoux J, Favier J, Scoazec JY, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 2014 ; 135 : 2711–2720.
Moog S, Lussey-Lepoutre C, Favier J. Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas. Endocr Relat Cancer 2020; 27 : R451–63.
Buffet A, Ben Aim L, Leboulleux S, et al. Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma. J Clin Endocrinol Metab 2019 ; 104 : 1109–1118.